Compare FLY & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLY | RGEN |
|---|---|---|
| Founded | 2017 | 1981 |
| Country | United States | United States |
| Employees | 1409 | N/A |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 6.6B |
| IPO Year | N/A | 1995 |
| Metric | FLY | RGEN |
|---|---|---|
| Price | $18.92 | $148.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 12 |
| Target Price | $38.88 | ★ $167.67 |
| AVG Volume (30 Days) | ★ 4.9M | 947.4K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 286.96 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $141,236,000.00 |
| Revenue This Year | $174.79 | $14.30 |
| Revenue Next Year | $66.73 | $14.52 |
| P/E Ratio | ★ N/A | $988.20 |
| Revenue Growth | N/A | ★ 35.10 |
| 52 Week Low | $16.00 | $100.99 |
| 52 Week High | $62.17 | $175.77 |
| Indicator | FLY | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 28.00 | 65.64 |
| Support Level | $18.07 | $141.44 |
| Resistance Level | $21.93 | $149.05 |
| Average True Range (ATR) | 2.02 | 4.96 |
| MACD | -0.41 | 0.30 |
| Stochastic Oscillator | 1.22 | 84.19 |
Firefly Aerospace Inc is a space and defense technology company with an established track record of success providing comprehensive mission solutions to national security, government, and commercial customers. The company develops and provides space and defense technologies, including launch vehicles and spacecraft systems, supporting launch, transit, and in-orbit operations for government, commercial, and national security customers. It has only one operating segment. The majority of the company's revenue is derived from Spacecraft Solutions.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.